In this issue:
Mediterranean anti-inflammatory diet and psoriasis severity
Tildrakizumab safety in moderate-to-severe plaque psoriasis
Adalimumab biosimilar GP2017 vs adalimumab in psoriasis
Patient-reported outcome measures for paediatric psoriasis
Nail involvement predictor of severity in paediatric psoriasis
Long-term methotrexate and liver cirrhosis in chronic hepatitis patients
Safety and efficacy of approved systemic psoriasis therapies
Serum IL-17A and clinical response to tofacitinib and etanercept
Latent tuberculosis infection and TNF inhibitors
TNF-α, IL-23 and IL-17A inhibitor effects on bodyweight and BMI
DLQI underestimates disease-specific burden
What’s new in psoriasis treatment?
Please login below to download this issue (PDF)